Big Pharma Embraces Pharmacogenomics - But Are We There Yet? - Biologics Market Research

Big Pharma Embraces Pharmacogenomics - But Are We There Yet?
Decision Resources
August 22, 2006
31 Pages
Pub ID: DECR1331474
US $1,900.00 PDF E-mail From Publisher
Abstract
Pharmacogenomics will revolutionize the drug industry by linking the right drug to the right patient. Several companies and regulatory agencies are leading the charge to implement this approach of developing targeted medicines. PGx's integration is inevitable; pharma companies must get on board now or risk being left behind.
Get the Answers You Need to Shape Your Strategy
Big pharma companies have become increasingly interested in PGx. These companies realize that PGx offers a way to develop better and safer drugs.
Which companies are leading the charge to integrate PGx into drug discovery and development?
Appropriate genetic markers and well-documented patient samples are critical to determining disease correlations.
How are companies obtaining this information, and how are they using it to create personalized medicines?
Although PGx is being integrated into many aspects of drug discovery and development, many regulatory and ethical challenges persist.
What are the major issues remaining, and what are companies and regulatory agencies doing to overcome these challenges?